Horizon Pharma,Inc.announced that it has entered into an agreement to acquire from AstraZeneca AB the U.S. rights to Vimovo (naproxen/esomeprazole...
VIMOVO is indicated in adults for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, in patients who are at risk for developing non-steroidal anti-inflammatory drug (NSAID)-associated gastric and/or duodenal ulcers and where treatment with lower doses of naproxen or of other NSAIDs is not considered sufficient.
AstraZeneca has agreed to divest the prescription medicine rights to Nexium (esomeprazole) in Europe, as well as the global rights (excluding the US and Japan) to Vimovo (naproxen/esomeprazole) to GrĂ¼nenthal.
AstraZeneca has announced that Qtrilmet (metformin hydrochloride, saxagliptin and dapagliflozin) modified-release tablets have been recommended for marketing authorisation in the...
• Secondary prevention of ischaemic stroke and transient ischaemic attacks either alone or in conjunction with aspirin. • An adjunct to oral anti-coagulation for prophylaxis of thromboembolism associated with prosthetic heart valves.
Non insulin-dependent diabetes (type 2) in adults when dietary measures, physical exercise and weight loss alone are not sufficient to control blood glucose.
Non-insulin dependent Diabetes mellitus (Type II) in adults when dietary measures, physical exercise and weight loss alone are not sufficient to control blood glucose.
Impax Laboratories, Inc.announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted...